This bill aims to extend the prohibition on drug manufacturers interfering with access to 340B drugs by repealing a specific provision in Minnesota Statutes. The provision being repealed is Minnesota Statutes 2024, section 62J.96, subdivision 3, which states that the section would expire on July 1, 2027.

By removing this expiration clause, the bill seeks to ensure that the protections for access to 340B drugs remain in effect indefinitely, thereby supporting healthcare providers and patients who rely on these medications. The legislative intent is to strengthen the framework around the availability of affordable drugs for those in need.

Statutes affected:
Introduction: 62J.96